Cellectis S.A.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- André Choulika
- Full Time Employees
- 229
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 8, rue de la Croix Jarry Paris IF France 75013
- IPO Date
- Jan 23, 2007
- Website
- cellectis.com
- Similar Companies
- Business
- Cellectis SA (Nasdaq:CLLS; Euronext Growth Paris:ALCLS) develops gene-edited allogeneic chimeric antigen receptor (CAR) T-cell immunotherapies using its proprietary TALEN gene-editing technology and PulseAgile electroporation system; the company pioneers off-the-shelf UCART product candidates, including UCART19, UCART22, UCART20x22 and UCART123, targeting hematological malignancies such as B-cell acute lymphoblastic leukemia and acute myeloid leukemia, as well as non-Hodgkin lymphoma and other solid tumors; manufacturing operations support clinical and commercial-scale production of these therapies through facilities producing plasmids, mRNA, viral vectors and GMP-grade UCART cells. Founded in 1999 and headquartered in Paris, France, with additional sites in New York and Raleigh, North Carolina, Cellectis operates primarily in the oncology immunotherapy segment, serving cancer patients through clinical-stage programs and partnerships. The company maintains a robust intellectual property portfolio exceeding 100 patent families and global collaborations with Allogene Therapeutics, Servier, Iovance Biotherapeutics, AstraZeneca and others. In recent developments, Cellectis strengthened its financial position with $264 million in cash as of December 31, 2024, bolstered by a $140 million equity investment from AstraZeneca and full drawdown of a $45.5 million European Investment Bank facility; AstraZeneca's joint research collaboration, initiated in 2023, yielded $47 million in payments by year-end 2024, including milestones for up to 10 novel products in oncology, immunology and rare diseases across three initial programs; both manufacturing sites achieved full operational status in 2022, enabling in-house production advancements.
Company News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
Cellectis S.A. (CLLS) Shareholders Who Lost Money – Contact Law Offices of Howard G.
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
Monthly information on share capital and company voting rights
Cellectis Unveils In Vivo Gene-Editing Plans for Severe Lipid Disorders
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
Cellectis S.A. (NASDAQ:CLLS) Stock Has Consensus Price Target of $5.46
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS
CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law
CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law
CLLS INVESTOR ALERT: Investigation of Cellectis S.A. Announced by Holzer & Holzer, LLC
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced -- Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm